Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lucie Ellis

Managing Editor, In Vivo

London, UK
Lucie Ellis has been covering the ups and downs of the pharmaceutical industry since joining the Informa Pharma Intelligence team in 2012. Prior to being Managing Editor of In Vivo, Lucie was a Senior Editor at Scrip and Pink Sheet. She is responsible for the production of In Vivo’s print and online editions and also contributes feature-length articles to the publication on the topics of leadership, R&D, innovation and more.
Advertisement
Set Alert for Articles By Lucie Ellis

Latest From Lucie Ellis

Hitting Refresh: Aduro CEO On Company Cuts, Pipeline Programs And Alliances

Aduro Biotech announced a “strategic reset” in January 2019 that will see the Californian company center around two core pipeline programs, cut its headcount and focus on pharma partnerships. Stephen Isaacs, chair, president and CEO of the company, speaks to In Vivo about his vision for Aduro as the 2020s approach, and the challenges a smaller biotech faces when balancing multiple big pharma agreements.

C-Suite Speaks Growth

How Will More Investor Cash Influence Biotech Deal-Making In 2019?

Biotech companies raised more than $22bn via venture capital financing in 2018. With more cash to propel innovation and bolster R&D, traditional pharma and biotech partnering agreements are likely to evolve in the year ahead.

Financing Market Intelligence

Verseon Playing The Long Game To Level Up Drug Discovery

Adityo Prakash, CEO and founder of Verseon, tells In Vivo more about his vision of re-routing the pharmaceutical industry with Verseon’s computational drug discovery technology. He also explains the company’s new subsidiary business, BlockRules, and how it fits into the biopharma world.

Research and Development Strategies Innovation

David Or Goliath: Where Is Innovation Winning Through?

With both a big pharma and biotech leadership perspective, David Meeker talks to In Vivo about how smaller firms can more easily fly solo in drug development, challenges effecting the innovative drug development sector in 2019 and the partnering environment for cell and gene therapy companies. 

Leadership Regenerative Medicine

In Vivo's Top M&A Of 2018: Cast Your Vote!

It is time for In Vivo's 11th annual Deals of the Year contest. We've selected 18 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)

Growth Deals

In Vivo's Top Financing Of 2018: Cast Your Vote!

It is time for In Vivo's 11th annual Deals of the Year contest. We've selected 18 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)

Deals Growth
See All
Advertisement
UsernamePublicRestriction

Register